Veru
D

VERU

1.94000
USD
-0.22
(-10.19%)
Market Closed
Last updated: · Delayed 15 min
Volume
5,892
EPS
-1
Div Yield
-
P/E
-3
Market Cap
33,077,621
Related Instruments

Title: Veru Inc

Sector: Healthcare
Industry: Biotechnology
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Common questions about Veru stock